Vertex Q3 revenue climbs 12% to $3.44bn as guidance increases

Vertex Pharmaceuticals (NASDAQ:VRTX) reported third-quarter 2026 revenue of $3.44 billion, up 12% year over year, and raised its full-year revenue guidance to $13.15 billion–$13.25 billion.

Revenue increased 10% in the United States to $2.17 billion and 16% internationally to $1.27 billion, supported by cystic fibrosis treatments and contributions from newer medicines.

GAAP net income declined to $654 million from $1.1 billion, primarily reflecting acquisition-related expenses, including approximately $500 million in compensation and transaction costs associated with Crinetics Pharmaceuticals.

Vertex raised its full-year revenue guidance from $13.1 billion–$13.2 billion to $13.15 billion–$13.25 billion, while expecting combined CASGEVY and JOURNAVX revenue of at least $500 million and PALSONIFY revenue of $40 million–$50 million.

The company completed its acquisition of Crinetics Pharmaceuticals on September 1, establishing a fourth commercial business in rare endocrine diseases, while preparing to expand into kidney disease through povetacicept, which has a regulatory decision date of November 30, 2026.

Vertex develops medicines for cystic fibrosis and other serious diseases, with its commercial portfolio including ALYFTREK, CASGEVY, JOURNAVX and PALSONIFY as it expands beyond its established cystic fibrosis business.